Member Registration

Members of LabOps Unite: please register here.
Members of BioCT: please register here.
Members of MassBio: please register on this page. Want your organization to gain access to member rates?  Email courses@massbioed.org for more information.

Rates & Funding

Please view the discount options for courses before registering here.

Member Rate: $1,275
Non-Member Rate: $1,500

Deadline to apply to the WTFP Express Program: September 28, 2026.
Course ID: C-3007

Single Company Offerings

Interested in offering this training exclusively to your team?
Email courses@massbioed.org to learn more.

Description

Biotech Commercialization: From Approval to Access explores the critical steps required to successfully bring biotechnology innovations to market after regulatory approval. Participants examine the intersection of science, business strategy, and regulatory frameworks that shape how new therapies reach patients and achieve commercial success.

Through interactive lectures, case studies, and applied learning, the course introduces key concepts including regulatory approval pathways, pricing and reimbursement dynamics, market access strategies, and product launch planning. Participants will also explore topics such as market assessment, strategic partnerships, and financial feasibility to better understand the complexities of biotech product commercialization and adoption.

Who should attend? This course is ideal for professionals working in or transitioning into roles related to commercialization, market access, product strategy, or business development within the biotechnology and life sciences industries. It is also valuable for scientists, project managers, and business professionals who want to better understand how innovative therapies move from regulatory approval to real-world patient access.

Participants interested in strengthening their understanding of the financial and operational aspects of commercialization may benefit from Finance of Biotechnology, and Biotechnology Project Management, which explore funding strategies, investment considerations, and project execution across the biotech lifecycle.

Schedule

Tuesday, October 20, 2026 | 9:00 AM – 5:00 PM EST
Wednesday, October 21, 2026 | 9:00 AM – 1:00 PM EST

Meet the Instructors

John Tagliamonte
SVP, Business Development, Tract Bio
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial operations, strategic planning, and legal functions across public and private life sciences companies. As MassBio’s first Entrepreneur-in-Residence, he helped shape forward-looking program content while mentoring the next generation of biotech entrepreneurs.

Atul Deshpande, Ph.D., MBA
CEO, IMMEDIATE Therapeutics
Atul Deshpande is the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical-stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes. Previously, he served as Chief Strategy Officer at Peptilogics and led Asia Pacific R&D strategy efforts for Sanofi in China.